CanSino Biologics (SEHK:6185) - Aktienkurs, Nachrichten und Analyse

6185 Aktienübersicht

CanSino Biologics Inc. entwickelt, produziert und vermarktet Impfstoffe in der Volksrepublik China.

6185 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

88.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 124.55% pro Jahr

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für 6185 festgestellt.

CanSino Biologics Inc. Wettbewerber

AIM Vaccine

SEHK:6660

HK$8.5b

Shanghai Junshi Biosciences

SEHK:1877

HK$26.5b

InnoCare Pharma

SEHK:9969

HK$9.5b

3SBio

SEHK:1530

HK$15.2b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für CanSino Biologics
Historische Aktienkurse
Aktueller Aktienkurs	HK$19.54
52-Wochen-Hoch	HK$33.20
52-Wochen-Tief	HK$14.80
Beta	0.53
11 Monat Veränderung	-7.61%
3 Monate Veränderung	22.74%
1 Jahr Veränderung	-25.28%
33 Jahre Veränderung	-94.83%
5 Jahre Veränderung	-47.75%
Veränderung seit IPO	-43.69%

Aktuelle Nachrichten und Updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01

Aktionärsrenditen

	6185	HK Biotechs	HK Markt
7D	-2.5%	-0.7%	-1.0%
1Y	-25.3%	-34.6%	0.7%

Rendite im Vergleich zur Industrie: 6185 übertraf die Branche Hong Kong Biotechs, die im vergangenen Jahr eine Rendite von -35.8 erzielte.

Rendite vs. Markt: 6185 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 2.7 erzielte.

Preisvolatilität

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement	10.1%
Biotechs Industry Average Movement	8.9%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 6185 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 6185Die wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2009	1,494	Xuefeng Yu	www.cansinotech.com

CanSino Biologics Inc. entwickelt, produziert und vermarktet Impfstoffe in der Volksrepublik China. Das Unternehmen entwickelt Convidecia und Ad5-nCoV für Inhalationsimpfstoffe gegen rekombinante neuartige Coronaviren, Ad5-EBOV, einen Impfstoff gegen Ebola-Viren, sowie MCV2- und MCV4-Impfstoffe für die Prävention von N. meningitides. Es entwickelt den DTcP-Impfstoff für Säuglinge und den DTcP-Booster-Impfstoff, die sich in der Phase I der klinischen Prüfung befinden, um den schwachen Schutz vor Keuchhusten nach der Erstimpfung zu verbessern.

CanSino Biologics Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von CanSino Biologics im Vergleich zum Marktanteil des Unternehmens?
6185 grundlegende Statistiken
Marktanteil	HK$7.64b
Gewinn(TTM)	-HK$1.63b
Umsatz(TTM)	HK$398.45m

12.1x

Kurs-Umsatz-Verhältnis

-3.0x

Kurs-Gewinn-Verhältnis

Ist 6185 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
6185 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥370.81m
Kosten der Einnahmen	CN¥781.88m
Bruttogewinn	-CN¥411.06m
Sonstige Ausgaben	CN¥1.10b
Umsatz	-CN¥1.51b

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Aug 30, 2024

Gewinn per Aktie (EPS)	-6.13
Bruttomarge	-110.85%
Nettogewinnspanne	-408.10%
Schulden/Eigenkapital-Verhältnis	47.5%

Wie hat sich 6185 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

6185 Aktienübersicht

Belohnungen

Risikoanalyse

CanSino Biologics Inc. Wettbewerber

SEHK:6660

HK$8.5b

SEHK:1877

HK$26.5b

SEHK:9969

HK$9.5b

SEHK:1530

HK$15.2b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

Erträge & Einnahmen